Pancreatic Cancer Clinical Trial
Official title:
Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination With VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer
This is a Phase I study evaluating the safety and feasibility of lentiviral transduced huCART-meso cells when given in combination with VCN-01 in a 3+3 dose (de)escalation design.
Status | Recruiting |
Enrollment | 12 |
Est. completion date | September 2038 |
Est. primary completion date | September 2038 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients with one of the following diagnoses: 1. Histologically confirmed unresectable or metastatic pancreatic adenocarcinoma; OR 2. Persistent or recurrent serous epithelial ovarian cancer 2. Progression or intolerance to at least one prior standard of care chemotherapy for advanced stage disease. 3. Subjects must have measurable disease as defined by RECIST 1.1 criteria. 4. Patients = 18 years of age. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. Adequate organ and bone marrow function defined as: 1. Hemoglobin = 9 g/dL 2. Platelets = 75,000/µl 3. PT/INR and PTT = 1.5 x ULN 4. Bilirubin = 2.0 x ULN 5. Creatinine = 1.5 x ULN 6. ALT/AST = 5 x ULN (subjects with liver metastases) or ALT/AST = 2.5 x ULN (subjects without liver metastases) 7. Must have a minimum level of pulmonary reserve defined as = Grade 1 dyspnea and pulse oxygen > 92% on room air 8. Left Ventricle Ejection Fraction (LVEF) = 40% confirmed by ECHO/MUGA 7. Provides written informed consent. 8. Subjects of reproductive potential must agree to use acceptable birth control methods, as described in the protocol Exclusion Criteria: 1. Patients with known CNS metastases 2. Active invasive cancer other than the one of the two cancers targeted by this study. Patients with active non-invasive cancers (such as non-melanoma skin cancer, superficial cervical and bladder and prostate cancer with PSA level < 1.0) are not excluded. 3. Active hepatitis B or hepatitis C infection. 4. Chronic hepatitis C with a FibroScan score equivalent to fibrosis stage 2 (F2) or greater. 5. Patients with known cirrhosis. 6. Patients with ongoing or active infection. 7. Patients with a known history of Li Fraumeni syndrome or retinoblastoma protein pathway germinal deficiency. 8. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to = 10 mg of prednisone. Patients with autoimmune neurologic diseases (such as MS) will be excluded. 9. Planned concurrent treatment with systemic high dose corticosteroids. Patients may be on a stable low dose of steroids (= 10mg equivalent of prednisone). Use of inhaled steroids is allowable. 10. Patients requiring supplemental oxygen therapy. 11. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40). 12. Any clinically significant pericardial effusion, Class II-IV cardiovascular disability according to the New York Heart Association Classification (see Appendix 4) or other cardiovascular condition that would preclude assessment of mesothelin induced pericarditis or that may worsen as a result of toxicities expected for this study. This determination will be made by a cardiologist if cardiac issues are suspected. 13. Pregnant or breastfeeding women. 14. Treatment with a PD-1 or PD-L1 inhibitor, including but not limited to nivolumab, pembrolizumab, atezolizumab, and/or durvalumab, within 2 months prior to eligibility confirmation by a physician-investigator. 15. Patients with significant lung disease as follows: 1. Patients with radiographic evidence of greater than lobar lymphangitic pulmonary involvement, greater than lobar bronchial wall thickening suggestive of peribronchial lymphatic disease extension, and/or evidence of extensive bilateral parenchymal metastatic burden. 2. Patients with radiographic and/or clinical evidence of active radiation pneumonitis. 3. Patients with radiographic evidence of underlying interstitial lung disease, including evidence of unresolved drug toxicity from any agent (e.g. chemotherapy, targeted agents, amiodarone, nitrofurantoin, etc.) |
Country | Name | City | State |
---|---|---|---|
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Pennsylvania | Theriva Biologics SL |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Type, frequency, severity, and attribution of AEs/SAEs as assessed by CTCAE v 5.0 | 2 years | ||
Primary | Occurrence of dose-limiting toxicities. | 2 years | ||
Secondary | Proportion of subjects enrolled who receive one or both of the intended study infusions | 2 years | ||
Secondary | Overall Response Rate (ORR) | 15 years | ||
Secondary | Best Overall Response (BOR) | 15 years | ||
Secondary | Duration of Response (DOR) | 15 years | ||
Secondary | Progression Free Survival (PFS) | 15 years | ||
Secondary | Overall Survival (OS) | 15 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|